Effects of different periods of lithium pretreatment and aminoglycoside antibiotics on apomorphine-induced yawning in rats

Pharmacology and Toxicology

Volumn 87, Issue 2, 2000, Pages 84-88

  Sharifzadeh, Mohammad ^a   Firooz, Elham Khajvand ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; APOMORPHINE; CALCIUM CHANNEL; GENTAMICIN; LITHIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; MALE; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; RAT; YAWNING;

ANIMALIA; POROMITRA OSCITANS;

EID: 0033896488     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2000.pto870207.x     Document Type: Article

References (29)

1. Barbizet, J.: Yawning. J. Neurosurg. Psychiat. 1958, 21, 203-207.
2. Berridge, M. J., C. P. Downes & M. R. Hanleg: Lithium amplifies agonist - dependent phosphatidyl inositol responses in brain and salivary glands. Biochem. J. 1982, 206, 587-595.
3. Bishop, W. P., J. August, J. M. Petrin & J. K. Pai: Regulation of sn-1,2-diacylglycerol second messenger formation in thrombin stimulated human platelets. Biochem. J. 1990, 269, 465-469.
4. Bitran, J. A., H. K. Manji, W. Z. Potter & F. Gusovsky: Down regulation of PKC alpha by lithium in vitro. Psychopharmacol. Bull. 1995, 31, 449-452.
5. Braun, A. R. & T. N. Chase: Obligatory D1/D2 receptor interaction related behaviours. Eur. J. Pharmacol. 1986, 131, 301-306.
6. Creese, I., D. R. Sibleg, M. W. Hamblin & S. E. Leff: The classification of dopamine receptors: relationship to radioligand binding. A. Rev. Neurosi. 1983, 6, 43-71.
7. Dehpour, A. R., M. Samini, M. Sharifzadeh & H. Hassan-Mazandarani: Effects of chronic lithium pretreatment on apomorphine-induced penile erection. Gen. Pharmacol. 1995, 26, 1015-1020.
8. Del-Rio, E., T. Shinomura, J. Van-der-kaay, D. G. Nichollas & C. P. Downes: Distribution by lithium of phosphoinositide signaling in cerebellar granule cells in primary culture. J. Neurochem. 1998, 70, 1662-1669.
9. Dziedzicka-Wasylewska, M., M. Mackowiak, K. Fijat & K. Wedzoney: Adaptive changes in the rat dopaminergic transmission following repeated lithium administration. J. Neural. Transm. Gen. Sect. 1996, 103, 765-776.
10. Ebstein, R. P., M. Hermoni & R. H. Belmaker: The effect of lithium on noradrenaline induced cAMP accumulation in rat brain; inhibition after chronic treatment and absence of supersensitivity. J. Pharmacol. Exp. Therap. 1980, 213, 161-167.
11. Friedman, E., L. Q. Jin, G. P. Cai, T. R. Hollon, J. Drago, D. R. Sibleg & H. Y. Wang: D1 like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. Mol. Pharmacol. 1997, 51, 6-11.
12. Hallcher, L. M. & W. R. Sherman: The effect of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 1980, 255, 10896-10901.
13. Jackson, P. M., O. F. Jackins & S. B. Ross: The motor effects of bromocriptine. A. Rev. Psychopharmacol. 1988, 95, 433-446.
14. Kebabian, J. N. & D. B. Calne: Multiple receptors of dopamine. Nature 1979, 227, 93-96.
15. Lippmann, S., W. Regan & M. Manshadi: Plasma lithium stability and a comparison of flame photometry and atomic absorption spectrophotometry analysis. Amer. J. Psychiatry. 1981, 138, 1375-1377.
16. Marinho, M. M., F. C. Sousa, V. M. Bruin, M. R. Vale & G. S. Viana: Effect of lithium, alone or associated with pilocarpine, on muscarinic and dopaminergic receptors and on phosphoinositide metabolism in rat hippocampus and striatum. Neurochem. Int. 1998, 33, 299-306.
17. Melis, M. A. & A. Argiolas: Apomorphine-induced penile erection and yawning: Site of action in brain. Brain Res. 1987, 415, 98-104.
18. Mingeot-Leclercq, M. P., G. Laurent & P. M. Tulkens: Biochemical mechanism of aminoglycoside induced inhibition of phosphatid-yl - coline hydrolysis by lysosomal phospholipases. Biochem. Pharmacol. 1989, 37, 591-599.
19. Nahorski, S. R., C. I. Ragan & R. A. J. Challis: Lithium and the phosphoinositide cycle: an example of uncompetelive inhibition and its pharmacological concequence. Trends Pharmacol. Sci. 1991, 12, 297-303.
20. Ocana, M. & J. M. Baeyens: Analgesic effects of centrally administered aminoglycoside antibiotics in mice. Neuroscience Lett. 1991, 126, 67-70.
21. Prien, R. F., D. J. Kupfer, P. A. Mansky, J. G. Small, V. B. Tuason, C. B. Voss & W. E. Johnson: Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorder. Report of the NIMH collaborative study group comparing lithium carbonate, imipiramine and a lithium carbonat-imipiramine combination. Arch. Gen. Psychiat. 1984, 41, 1096-1104.
22. Schou, M.: Lithium in psychiatric therapy and prophylaxis. J. Psychiat. Res. 1968, 6, 67-95.
23. Seeman, P.: Brain dopamine connection. Nature 1980, 342, 121-122.
24. Sharifzadeh, M., A. R. Dehpour, M. Samini, H. Hassan-Mazandarani, T. Sammadian & G. H. Asghari: Alterations of bromocriptine-induced penile erection by chronic lithium in rats. J. Psychopharmacol. 1996, 10, 157-161.
25. Sharifzadeh, M., M. Abdollahi, A. R. Dehpour, A. Kebriaeezadeh, M. Samini & M. Mohammad: Alteration of physostigmine-induced yawning by chronic lithium administration in rats. Pharmacology & Toxicology 1997, 81, 159-163.
26. Sharifzadeh, M., M. Abdollahi, H. Behrooz, B. Minaii, A. Kebriaeezadeh, M. Rezvani, A. R. Dehpour & N. Aghaebrahimi: Effects of chronic lithium on ototoxicity induced by gentamicin and amikacin in guinea-pigs. Pharmacology & Toxicology 1998, 83, 220-224.
27. Stoof, J. C. & J. W. Kebabian: Two dopamine receptors. Biochem. Pharmacol. Life Sci. 1984, 35, 2281-2296.
28. Vallar, L., C. Muca, M. Magni, P. Albert, J. Bunzow, J. Meldolesi & O. Civelli: Differential coupling of dopaminergic D2 receptors expressed in different cell types. J. Biol. Chem. 1990, 265, 10320-10326.
29. Wood, A. J., G. M. Goodwin, R. De Souza & A. R. Green: The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug. Neuropharmacology 1986, 25, 1285-1288.